Quick Answer
SELLAS Life Sciences Group, Inc. reported Diluted EPS of $0.25 per share (loss) for fiscal year 2025.
SELLAS Life Sciences Group, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.25 | +50.0% |
| 2024 | -$0.50 | +62.7% |
| 2023 | -$1.34 | +37.1% |
| 2022 | -$2.13 | -59.0% |
| 2021 | -$1.34 | +36.5% |
| 2020 | -$2.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.06 | +40.0% | +14.3% |
| June 30, 2025 | -$0.07 | +46.2% | +0.0% |
| March 31, 2025 | -$0.07 | +66.7% | +30.0% |
| September 30, 2024 | -$0.10 | +69.7% | +23.1% |
| June 30, 2024 | -$0.13 | +58.1% | +38.1% |
| March 31, 2024 | -$0.21 | +55.3% | +36.4% |
| September 30, 2023 | -$0.33 | +2.9% | -6.5% |
| June 30, 2023 | -$0.31 | +24.4% | +34.0% |
- SELLAS Life Sciences Group, Inc. showed an increase of +50.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, SELLAS Life Sciences Group, Inc.’s diluted eps has grown by 88.2% (from $2.11 per share (loss) to $0.25 per share (loss)).
- The most recent figure is from SELLAS Life Sciences Group, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: